Go Pro
→ Gold Miners Post Record Cash Flow Even as Prices Pull Back (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$24.77
+0.1%		$21.44
$11.92
▼
$26.16
$3.95B2.082.63 million shs2.67 million shs
ALMR
Alamar Biosciences
$32.13
-3.1%		$25.88
$18.84
▼
$38.54
$2.30BN/A295,000 shs193,775 shs
Azenta, Inc. stock logo
AZTA
Azenta
$33.58
+0.6%		$26.87
$15.93
▼
$41.73
$1.46B1.36669,480 shs533,125 shs
Sotera Health Company stock logo
SHC
Sotera Health
$18.80
-0.5%		$17.55
$13.09
▼
$19.85
$5.39B1.773.01 million shs7.82 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+0.12%-2.67%+8.07%+91.13%+89.95%
ALMR
Alamar Biosciences
-3.11%+14.79%+23.82%+56.66%+3,212,999,900.00%
Azenta, Inc. stock logo
AZTA
Azenta
+0.60%+0.75%+27.73%+90.25%+10.50%
Sotera Health Company stock logo
SHC
Sotera Health
-0.48%-0.90%+5.92%+23.44%+19.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$24.77
+0.1%		$21.44
$11.92
▼
$26.16
$3.95B2.082.63 million shs2.67 million shs
ALMR
Alamar Biosciences
$32.13
-3.1%		$25.88
$18.84
▼
$38.54
$2.30BN/A295,000 shs193,775 shs
Azenta, Inc. stock logo
AZTA
Azenta
$33.58
+0.6%		$26.87
$15.93
▼
$41.73
$1.46B1.36669,480 shs533,125 shs
Sotera Health Company stock logo
SHC
Sotera Health
$18.80
-0.5%		$17.55
$13.09
▼
$19.85
$5.39B1.773.01 million shs7.82 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+0.12%-2.67%+8.07%+91.13%+89.95%
ALMR
Alamar Biosciences
-3.11%+14.79%+23.82%+56.66%+3,212,999,900.00%
Azenta, Inc. stock logo
AZTA
Azenta
+0.60%+0.75%+27.73%+90.25%+10.50%
Sotera Health Company stock logo
SHC
Sotera Health
-0.48%-0.90%+5.92%+23.44%+19.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.57
Moderate Buy$24.42-1.43% Downside
ALMR
Alamar Biosciences
2.43
Hold$31.80-1.03% Downside
Azenta, Inc. stock logo
AZTA
Azenta
2.43
Hold$41.2022.69% Upside
Sotera Health Company stock logo
SHC
Sotera Health
2.73
Moderate Buy$21.5014.36% Upside

Current Analyst Ratings Breakdown

Latest AZTA, SHC, ADPT, and ALMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
ALMR
Alamar Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
8/11/2026
Azenta, Inc. stock logo
AZTA
Azenta
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
Sotera Health Company stock logo
SHC
Sotera Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/11/2026
ALMR
Alamar Biosciences
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$28.00 ➝ $32.00
8/11/2026
ALMR
Alamar Biosciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$32.00 ➝ $35.00
8/7/2026
Sotera Health Company stock logo
SHC
Sotera Health
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$23.00 ➝ $25.00
8/7/2026
Sotera Health Company stock logo
SHC
Sotera Health
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$19.00 ➝ $22.00
8/7/2026
Sotera Health Company stock logo
SHC
Sotera Health
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$22.00 ➝ $25.00
8/7/2026
Sotera Health Company stock logo
SHC
Sotera Health
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$16.00 ➝ $18.00
8/5/2026
Azenta, Inc. stock logo
AZTA
Azenta
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$33.00 ➝ $37.00
8/4/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$20.00 ➝ $27.50
(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$308.08M12.83N/AN/A$1.47 per share16.85
ALMR
Alamar Biosciences
$74.21M30.04N/AN/AN/A∞
Azenta, Inc. stock logo
AZTA
Azenta
$593.82M2.48$1.82 per share18.42$37.67 per share0.89
Sotera Health Company stock logo
SHC
Sotera Health
$1.16B4.61$1.27 per share14.78$2.13 per share8.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.41N/AN/AN/A-20.73%-36.81%-13.77%11/4/2026 (Estimated)
ALMR
Alamar Biosciences
-$29.82M-$1.74N/AN/AN/AN/AN/AN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
-$55.76M-$2.76N/AN/AN/A-20.63%1.18%0.97%N/A
Sotera Health Company stock logo
SHC
Sotera Health
$77.94M$0.5732.9819.38N/A13.44%40.12%7.55%11/3/2026 (Estimated)

Latest AZTA, SHC, ADPT, and ALMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
ALMR
Alamar Biosciences
-$0.36-$0.22+$0.14-$0.22N/A$29.43 million
8/6/2026Q2 2026
Sotera Health Company stock logo
SHC
Sotera Health
$0.2389$0.26+$0.0211$0.19$309.70 million$321.38 million
8/4/2026Q3 2026
Azenta, Inc. stock logo
AZTA
Azenta
$0.1138$0.16+$0.0462$0.05$149.31 million$161.18 million
7/29/2026Q2 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.1336-$0.25-$0.1164-$0.25$65.44 million$71.55 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
N/AN/A-100.00%N/AN/A
Sotera Health Company stock logo
SHC
Sotera Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.22
4.79
4.68
ALMR
Alamar Biosciences
0.03
11.85
10.23
Azenta, Inc. stock logo
AZTA
Azenta
N/A
2.50
2.21
Sotera Health Company stock logo
SHC
Sotera Health
3.33
2.80
2.55

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
ALMR
Alamar Biosciences
N/A
Azenta, Inc. stock logo
AZTA
Azenta
99.08%
Sotera Health Company stock logo
SHC
Sotera Health
91.03%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5.70%
ALMR
Alamar Biosciences
N/A
Azenta, Inc. stock logo
AZTA
Azenta
10.90%
Sotera Health Company stock logo
SHC
Sotera Health
15.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790159.60 million150.50 millionOptionable
ALMR
Alamar Biosciences
22269.39 millionN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
3,00043.81 million39.03 millionOptionable
Sotera Health Company stock logo
SHC
Sotera Health
3,000285.38 million241.54 millionOptionable

Recent News About These Companies

State of Wyoming Buys Shares of 56,651 Sotera Health Company $SHC
August 16 at 7:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-state-of-wyoming-buys-shares-of-56651-sotera-health-company-shc-2026-08-16/
Sotera Health Company (SHC): Buy, sell, or hold post Q2 earnings?
August 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/sotera-health-company-shc-buy-sell-or-hold-post-q2-earnings/ar-AA2a61vF
Sotera Health Company’s Q2 earnings call: Our top 5 analyst questions
August 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/sotera-health-company-s-q2-earnings-call-our-top-5-analyst-questions/ar-AA2a1m1W
Sotera Health (SHC) Q2 2026 Earnings Call Transcript
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sotera-health-shc-q2-2026-132923797.html
Michael Rutz Sells 150,000 Shares of Sotera Health (NASDAQ:SHC) Stock
August 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30958873
Insider Selling: Sotera Health (NASDAQ:SHC) Insider Sells $2,826,000.00 in Stock
August 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-shc-insider-buying-and-selling-2026-08-12/
Sotera Health (NASDAQ:SHC) Insider Sells $2,826,000.00 in Stock
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sotera-health-nasdaqshc-insider-sells-282600000-in-stock-2026-08-11/
Sotera Health Company (NASDAQ:SHC) Given Average Recommendation of "Moderate Buy" by Analysts
August 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30953559
Sotera Health Company (SHC) Reported Positive Results Amid Litigation Wins
August 10, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/sotera-health-company-shc-reported-positive-results-amid-litigation-wins-1808646/
Quantinno Capital Management LP Has $2.83 Million Position in Sotera Health Company $SHC
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-has-283-million-position-in-sotera-health-company-shc-2026-08-10/
Sotera Health's (SHC) Overweight Rating Reiterated at Piper Sandler
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951507
Sotera Health (NASDAQ:SHC) Price Target Raised to $18.00
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951514
Renaissance Technologies LLC Reduces Holdings in Sotera Health Company $SHC
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-reduces-holdings-in-sotera-health-company-shc-2026-08-09/
Bullfrog AI (NASDAQ:BFRGW) versus Sotera Health (NASDAQ:SHC) Head to Head Comparison
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30950622
SHC Q2 deep dive: Broad-based growth, leadership transition, and strategic investments shape outlook
August 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/shc-q2-deep-dive-broad-based-growth-leadership-transition-and-strategic-investments-shape-outlook/ar-AA29Aj9y
Sotera Health (NASDAQ:SHC) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sotera-health-nasdaqshc-posts-quarterly-earnings-results-beats-estimates-by-002-eps-2026-08-07/
Piper Sandler Reaffirms "Overweight" Rating for Sotera Health (NASDAQ:SHC)
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/piper-sandler-reaffirms-overweight-rating-for-sotera-health-nasdaqshc-2026-08-07/
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Sotera Health (NASDAQ:SHC) Stock
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-forecasts-strong-price-appreciation-for-sotera-health-nasdaqshc-stock-2026-08-07/
Sotera Health Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sotera-health-q2-earnings-call-highlights-2026-08-07/
Balefire LLC Lowers Position in Sotera Health Company $SHC
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-balefire-llc-lowers-position-in-sotera-health-company-shc-2026-08-07/
Sotera Health Company 2026 Q2 - Results - Earnings Call Presentation
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932360-sotera-health-company-2026-q2-results-earnings-call-presentation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$24.77 +0.03 (+0.12%)
As of 08/17/2026 04:00 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Alamar Biosciences NASDAQ:ALMR

$32.13 -1.03 (-3.11%)
As of 08/17/2026 04:00 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Azenta stock logo

Azenta NASDAQ:AZTA

$33.58 +0.20 (+0.60%)
As of 08/17/2026 04:00 PM Eastern

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Sotera Health stock logo

Sotera Health NASDAQ:SHC

$18.80 -0.09 (-0.48%)
As of 08/17/2026 04:00 PM Eastern

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas